Venetoclax

The optimum approach to frontline treatment of CLL in 2021 2:51
The optimum approach to frontline treatment of CLL in 2021
Barbara Eichhorst • 6 Sep 2021
Patient segmentation for targeted therapy in myeloma 4:52
Patient segmentation for targeted therapy in myeloma
Faith Davies et al. • 11 Sep 2021
Treatment-free intervals: what is best for patients? 4:02
Treatment-free intervals: what is best for patients?
Phil McCarthy • 1 Sep 2021
Long-term management of CLL for improved outcomes 2:19
Long-term management of CLL for improved outcomes
Catherine C. Coombs • 9 Sep 2021
BTKi resistance and it’s management 2:33
BTKi resistance and it’s management
Jennifer Woyach • 26 Aug 2021
The frontline treatment strategy for newly diagnosed AML 5:11
The frontline treatment strategy for newly diagnosed AML
Tapan Kadia • 26 Aug 2021
Seizing the day with BTK inhibitors in CLL 3:29
Seizing the day with BTK inhibitors in CLL
Jennifer Woyach • 26 Aug 2021
The 2021 treatment algorithm for FLT3-mutated AML 6:47
The 2021 treatment algorithm for FLT3-mutated AML
Naval Daver • 26 Aug 2021
Progress in the treatment of TP53 mutated AML 8:14
Progress in the treatment of TP53 mutated AML
Naval Daver • 26 Aug 2021
Treating high risk CLL with BTK inhibitors 1:41
Treating high risk CLL with BTK inhibitors
Deborah M. Stephens • 31 Aug 2021
Novel approaches to treating AML in elderly patients 3:29
Novel approaches to treating AML in elderly patients
Tapan Kadia • 26 Aug 2021
Early relapse: options for rescue 2:25
Early relapse: options for rescue
Maria-Victoria Mateos • 2 Sep 2021
Novel agents for Waldenström’s macroglobulinemia 3:57
Novel agents for Waldenström’s macroglobulinemia
Jorge Castillo • 20 Aug 2021
Optimizing conventional chemotherapy in ALL 4:31
Optimizing conventional chemotherapy in ALL
Matthew Wieduwilt • 25 Aug 2021
New therapies for amyloidosis 1:27
New therapies for amyloidosis
Angela Dispenzieri • 18 Aug 2021
Ongoing trials in amyloidosis 2:32
Ongoing trials in amyloidosis
Angela Dispenzieri • 18 Aug 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals